Asuragen, microRNA Rx Subsidiary Awarded NIH Grants to Support Rx, Dx-Development
September 30, 2010
Asuragen, microRNA Rx Subsidiary Awarded NIH Grants to Support Rx, Dx-Development
The grant issued to Asuragen will help the company identify miRNA biomarkers for colon cancer recurrence, while Mirna Therapeutics' grant will fund its efforts to develop prostate cancer drugs based on the small, non-coding RNAs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NIH Awards $1.2M in Grants to Four Companies Developing RNAi, miRNA Cancer Drugs
October 4, 2012 / Gene Silencing News - NIH Awards Three Grants Supporting RNAi, microRNA Rx Development
July 8, 2010 / Gene Silencing News - NIH Awards $400K to Fund Three microRNA Research Grants in May
May 23, 2013 / Gene Silencing News - NIH Awards Nearly $2M in microRNA Research Grants
April 18, 2013 / Gene Silencing News - NIH Awards Nearly $1M in microRNA-Related Research Grants in July
July 26, 2012 / Gene Silencing News